Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of utidelone in breast cancer (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 60 months. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05172518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172518.